Evidence map›Paper›PMID 37533352›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

Fragment-based design, synthesis and biological evaluation of theophylline derivatives as ATAD2 inhibitors in BT-549 cells.

Dahong Yao, Jieshu You, Xuetao Yang, Jin Zhang, Xiaojun Yao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Dahong YaoState Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, China.
Jieshu YouSchool of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen, China.
Xuetao YangSchool of Pharmaceutical Sciences, Shenzhen Technology University, Shenzhen, China.
Jin ZhangSchool of Pharmaceutical Sciences, Medical School, Shenzhen University, Shenzhen, China.
Xiaojun YaoState Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, China.
Shenzhen Technology University · CNQuality Research · USShenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ATPase family AAA domain-containing protein 2 (ATAD2) has been emerging as a hot anti-cancer drugable target due to its oncogenic epigenetic modification closely associated with cancer cells proliferation, apoptosis, migration and drug resistance. In this study, we design a series of theophylline derivatives as novel ATAD2 inhibitors through fragment-based screening and scaffold growth strategy. A novel potent ATAD2 inhibitor (compound

Indexed as

NeoplasmsTheophyllineAdenosine TriphosphatasesATPases Associated with Diverse Cellular ActivitiesCell ProliferationDNA-Binding ProteinsHumansAdenosine TriphosphatasesATAD2 protein, humanATPases Associated with Diverse Cellular ActivitiesDNA-Binding ProteinsTheophyllineapoptosisATAD2fragment-basedmigrationTNBC

Identifiers

PMID37533352
PMCPMC10402865
OpenAlexW4385514171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.